For a German mid-sized pharmaceutical company, undergoing a radical restructuring as it transitioned into new therapeutic areas, I worked with the executive management group to improve the company’s R&D investment productivity. This involved developing a more thorough understanding of the development and market uncertainties the company faced, and the proactive creation of new alternatives to exploit this.